Vestmark Advisory Solutions Inc. Cuts Stock Position in Abbott Laboratories $ABT

Vestmark Advisory Solutions Inc. trimmed its position in Abbott Laboratories (NYSE:ABT) by 26.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,066 shares of the healthcare product maker’s stock after selling 12,452 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Abbott Laboratories were worth $4,563,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in ABT. Cloud Capital Management LLC purchased a new position in Abbott Laboratories during the 3rd quarter worth $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $31,000. Anfield Capital Management LLC increased its holdings in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories in the 2nd quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter worth approximately $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $115.14 on Tuesday. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a market cap of $200.20 billion, a PE ratio of 30.95, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. The business has a 50-day simple moving average of $118.19 and a 200-day simple moving average of $125.68.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the business earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Acquisition strategy could expand diagnostics/oncology exposure — Abbott announced plans tied to acquiring Exact Sciences and market commentary highlights the strategic upside of bolstering cancer‑screening capabilities. QuiverQuant: Acquisition discussion
• Positive Sentiment: Dividend maintained — Abbott declared a quarterly dividend ($0.63/share, ex‑date April 15), supporting income investors and signaling cash‑flow confidence. (Company release)
• Positive Sentiment: Analyst backing and price targets — Several firms maintain buy/overweight ratings and median targets (~$140), providing upside vs. the current trading level and helping buyer confidence. QuiverQuant: Analyst ratings and targets
• Neutral Sentiment: Q4 results were mixed — EPS matched consensus ($1.50) but revenue modestly missed estimates; management gave Q1 and FY 2026 EPS ranges that investors are parsing for cadence of recovery. Zacks: Q4 recap
• Neutral Sentiment: Valuation debate amid recent weakness — Commentary examines whether recent share weakness makes ABT attractive or merely fairly valued given sector headwinds; this frames some buying interest. Yahoo: Valuation piece
• Negative Sentiment: Big bond sale to fund Exact Sciences deal raises leverage concerns — Abbott’s planned ~$20B bond issuance to finance the acquisition has prompted debate over increased debt in a tighter rate environment. QuiverQuant: Bond financing discussion
• Negative Sentiment: Product‑liability lawsuit involving FreeStyle Libre 3 — A wrongful‑death suit alleges defects in Libre 3 systems, naming Abbott and raising regulatory, safety and potential litigation cost risks. This is a material legal overhang to monitor. Yahoo: Wrongful‑death lawsuit

Analyst Ratings Changes

ABT has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Citigroup cut their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Evercore cut their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Barclays decreased their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.